Zacks: Brokerages Expect Retrophin Inc (RTRX) to Announce -$0.27 EPS

Analysts expect Retrophin Inc (NASDAQ:RTRX) to post earnings of ($0.27) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Retrophin’s earnings, with the highest EPS estimate coming in at $0.10 and the lowest estimate coming in at ($0.64). Retrophin posted earnings of $0.01 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 2,800%. The company is expected to announce its next earnings report on Thursday, May 3rd.

On average, analysts expect that Retrophin will report full year earnings of $0.09 per share for the current fiscal year, with EPS estimates ranging from ($0.77) to $0.94. For the next year, analysts forecast that the business will post earnings of $0.59 per share, with EPS estimates ranging from $0.33 to $0.85. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Retrophin.

How to Become a New Pot Stock Millionaire

Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.20). The business had revenue of $42.18 million for the quarter, compared to analyst estimates of $42.20 million. Retrophin had a negative return on equity of 13.98% and a negative net margin of 38.55%.

RTRX has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Retrophin from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 4th. BidaskClub cut shares of Retrophin from a “buy” rating to a “hold” rating in a research report on Saturday, December 30th. BMO Capital Markets cut their target price on shares of Retrophin from $44.00 to $43.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, ValuEngine cut shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Saturday, February 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $43.00.

RTRX traded up $0.24 during midday trading on Monday, reaching $23.48. 264,786 shares of the company’s stock were exchanged, compared to its average volume of 234,780. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.74 and a current ratio of 3.80. Retrophin has a 1-year low of $15.55 and a 1-year high of $26.44.

Institutional investors and hedge funds have recently made changes to their positions in the business. Trexquant Investment LP acquired a new position in Retrophin during the third quarter worth about $203,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Retrophin in the third quarter valued at approximately $212,000. Teacher Retirement System of Texas acquired a new position in shares of Retrophin in the fourth quarter valued at approximately $256,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Retrophin in the third quarter valued at approximately $349,000. Finally, SG Americas Securities LLC raised its position in shares of Retrophin by 78.5% in the third quarter. SG Americas Securities LLC now owns 14,580 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 6,413 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Expect Retrophin Inc (RTRX) to Announce -$0.27 EPS” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3338917/zacks-brokerages-expect-retrophin-inc-rtrx-to-announce-0-27-eps.html.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Get a free copy of the Zacks research report on Retrophin (RTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Rentokil Initial  Stock Rating Lowered by Deutsche Bank
Rentokil Initial Stock Rating Lowered by Deutsche Bank
Nielsen  Stock Rating Upgraded by BMO Capital Markets
Nielsen Stock Rating Upgraded by BMO Capital Markets
Countryside Properties  Price Target Raised to GBX 410
Countryside Properties Price Target Raised to GBX 410
Randgold Resources  Given a $100.00 Price Target at Desjardins
Randgold Resources Given a $100.00 Price Target at Desjardins
The J.M. Smucker  Cut to “Sell” at Credit Suisse Group
The J.M. Smucker Cut to “Sell” at Credit Suisse Group
Sensient Technologies  Earning Somewhat Positive News Coverage, Study Finds
Sensient Technologies Earning Somewhat Positive News Coverage, Study Finds


Leave a Reply

© 2006-2018 Ticker Report. Google+.